Mastering Prolonged Analgesia: Sourcing High-Purity Bupivacaine Base API (CAS 2180-92-9)
Aug 08, 2026
Leave a message
The Gold Standard of Prolonged Analgesia: Engineering Bupivacaine Base API (CAS 2180-92-9)
An R&D Whitepaper on Sodium Channel Blockade, Liposomal Delivery Systems, and High-Fidelity Anesthetic Manufacturing.
In this demanding landscape, Bupivacaine remains the undisputed gold standard for long-acting local anesthesia. However, formulating next-generation anesthetic delivery systems-such as slow-release liposomal suspensions or targeted transdermal patches-requires a highly specific chemical starting point. Standard aqueous Bupivacaine Hydrochloride falls short for these lipid-based technologies. R&D directors require the highly lipophilic Bupivacaine Base (CAS 2180-92-9). This technical dossier dissects the distinct pharmacokinetic advantages of the free base form, the biological mechanics of voltage-gated sodium channel inhibition, and the exacting, high-purity chemical synthesis protocols executed at Xi'an Tihealth.
1. Molecular Architecture: Silencing the Nerve Action Potential
To engineer safe and effective regional anesthetic formulations, chief scientific officers must deeply understand the physicochemical properties that dictate nerve penetration. Bupivacaine (C18H28N2O) is a potent amide-type local anesthetic. Structurally, it is distinguished from lidocaine by the substitution of a butyl group on the piperidine nitrogen, a seemingly minor modification that exponentially alters its pharmacological profile.
Voltage-Gated Sodium Channel (Nav) Blockade
The transmission of acute pain relies on the rapid influx of sodium ions (Na+) across the neuronal membrane, which propagates the action potential toward the central nervous system. Bupivacaine functions by diffusing through the lipid bilayer of the nerve sheath and binding directly to the intracellular portion of the voltage-gated sodium channels. By physically occluding this channel, Bupivacaine halts the Na+ influx, completely preventing membrane depolarization and effectively silencing the pain signal at the surgical or trauma site.
Lipid Solubility & Prolonged Duration of Action
The addition of the butyl chain makes Bupivacaine highly lipophilic-significantly more so than short-acting anesthetics like lidocaine or mepivacaine. This extreme lipid solubility allows the molecule to aggressively partition into the lipid-rich myelin sheath of neuronal axons. Consequently, the drug binds with tremendous affinity to the nerve tissue, resisting rapid systemic clearance by the bloodstream. This translates into a duration of action that can last up to 8 hours from a single administration, providing unparalleled post-operative pain relief.
The Differential Blockade Phenomenon
A unique and highly desirable clinical trait of Bupivacaine is its tendency to produce a "differential block." At optimized concentrations, it effectively blocks the smaller, unmyelinated sensory nerve fibers (C-fibers) responsible for transmitting pain, while largely sparing the larger, myelinated motor fibers (A-alpha fibers). For applications such as epidural analgesia during labor and delivery, this means the patient experiences profound pain relief while maintaining essential motor function.
2. Formulation Strategy: Bupivacaine Base vs. Hydrochloride Salt
A critical misstep in pharmaceutical procurement is misunderstanding the phase behavior of anesthetic salts. To successfully develop advanced delivery systems, R&D teams must select the exact chemical form that aligns with their excipient matrix.
| Physicochemical Property | Bupivacaine Hydrochloride (CAS 14252-80-3) | Xi'an Tihealth Bupivacaine Base API (CAS 2180-92-9) |
|---|---|---|
| Aqueous Solubility | Highly soluble in water | Practically insoluble in water |
| Lipid/Organic Solubility | Poor solubility in lipids and oils | Highly soluble in alcohols, lipids, and organic solvents |
| Primary Formulation Use | Standard aqueous injectables (vials/ampoules) for immediate regional blocks. | Advanced lipid-based slow-release technologies, liposomal encapsulation, and non-aqueous topical gels. |
| Membrane Penetration Speed | Must shed the proton in physiological pH to cross the nerve sheath. | Exists entirely as the uncharged, lipophilic free base; immediately penetrates lipid membranes. |
3. The Xi'an Tihealth Advantage: Forensic Chemical Synthesis
Local anesthetics have a narrow therapeutic index. Systemic absorption of low-quality API can lead to Local Anesthetic Systemic Toxicity (LAST), a potentially fatal cardiovascular event. The danger often lies not in the Bupivacaine itself, but in the highly toxic synthetic impurities left behind by crude manufacturing processes-specifically the residual presence of 2,6-dimethylaniline, a known cytotoxic and genotoxic intermediate.
At Xi'an Tihealth Biotechnology Co., Ltd., we treat our amide synthesis protocols with uncompromising forensic rigor, engineered for absolute chemical purity and biological safety:
Targeting 2,6-Dimethylaniline
The synthesis of Bupivacaine typically involves the coupling of pipecolic acid derivatives with 2,6-xylidine. Unreacted 2,6-xylidine (dimethylaniline) is highly toxic. We utilize multi-stage fractional crystallization and targeted pH-swing extraction to relentlessly purge this intermediate, ensuring our final API tests well below the stringent parts-per-million (ppm) limits set by international pharmacopeias.
USP <467> Solvent Control
Chemical synthesis requires organic solvents, but the final medical product must not. Xi'an Tihealth employs proprietary closed-loop solvent recovery systems and intense high-vacuum purging ovens. We guarantee that residual solvents fall strictly below the Class 2 and Class 3 thresholds mandated by the United States Pharmacopeia (USP <467>).
HPLC & Loss on Drying Audit
We do not rely on theoretical chemistry. Every batch of Bupivacaine Base is forensically audited via High-Performance Liquid Chromatography (HPLC) to yield an uncompromising ≥ 99.0% purity. Furthermore, strict Karl-Fisher moisture titration ensures a completely dry, non-clumping powder perfect for high-speed automated encapsulation or blending.
4. Industrial Application Scenarios for Bupivacaine Base
Because Bupivacaine Base (CAS 2180-92-9) is highly lipophilic, it unlocks advanced, highly lucrative product categories that standard aqueous hydrochloride salts simply cannot support:
Liposomal Sustained-Release Injectables
The future of post-operative care. By encapsulating the lipophilic Bupivacaine Base inside multivesicular liposomes, formulators can create advanced suspensions that slowly release the anesthetic over 72 to 96 hours, completely eliminating the need for post-surgical opioid prescriptions.
Topical Transdermal Anesthetic Patches
For localized neuropathic pain management. The free base form easily integrates into lipid-based polymer matrices and deeply penetrates the stratum corneum (the skin's outermost lipid barrier), a feat that water-soluble hydrochloride salts struggle to achieve.
Dental & Orthopedic Depot Suspensions
Ideal for compounding pharmacies developing specialized, non-aqueous anesthetic pastes or biodegradable polymer implants designed to be packed into dental extraction sites or orthopedic surgical cavities for prolonged numbing.
Veterinary Regional Anesthesia
Highly sought after by veterinary pharmaceutical developers creating long-acting ring blocks and local infiltrations for large animal surgeries, where prolonged pain management is essential for safe recovery and humane care.
Formulator & Procurement FAQ
Lidocaine is an excellent rapid-onset anesthetic, but it is quickly washed out of the nerve tissue by regional blood flow, limiting its efficacy to 1-2 hours. Bupivacaine's highly lipophilic structure allows it to bind tenaciously to the neuronal protein channels, extending the duration of the pain block to 4-8 hours (and up to 72 hours when formulated into liposomes). For true post-surgical pain management without opioids, Bupivacaine is the mandatory choice.
Following precision vacuum drying to eliminate trace moisture, our high-purity crystalline powder is packaged in robust 25KG fiber drums lined with double-layer, pharmaceutical-grade polyethylene (PE) bags. For added security during global maritime transit, the product is sealed under an inert nitrogen flush to prevent oxidative degradation, guaranteeing a stable 24-month shelf life when stored away from direct light and heat.
Absolutely. Xi'an Tihealth operates strictly within ISO9001:2015 and GMP-aligned quality frameworks. Every commercial batch of Bupivacaine Base is dispatched with a comprehensive technical dossier. This includes a detailed Certificate of Analysis (COA), high-resolution HPLC chromatograms confirming ≥ 99.0% purity, and strict heavy metal and solvent residue testing data, ensuring seamless integration into your downstream R&D and QA processes.
Engineer the next generation of prolonged pain management with high-purity API.
Request HPLC Chromatogram & Bulk PricingWritten by Wang Xueyan, Technical Operations & Formulation Strategy at Xi'an Tihealth Biotechnology Co., Ltd.
*Compliance Disclaimer: Provided exclusively as an unformulated, research-grade Active Pharmaceutical Ingredient (API). Purchasing organizations are solely responsible for final formulation, clinical testing, compounding safety, and strict regulatory alignment within their respective global jurisdictions.*
Send Inquiry